Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Metiprenaline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 4/20 | 0.70 |
| ▸ | ADRB1 known ✓ | P08588 | 3/20 | 0.70 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.70 |
| ▸ | ADRB3 known ✓ | P13945 | 3/20 | 0.68 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.68 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.68 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.68 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.68 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.68 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.68 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.68 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | TSHR | P16473 | 4/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.70 |
| ▸ | BLM | P54132 | 4/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 3/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metiprenaline SCHEMBL3220256 | 1.00 | SLC22A3 (0.97) | SLC22A3MAPTADRB2TSHRKDM4E | |
| Metiprenaline SCHEMBL3217916 | 0.98 | SLC22A3 (1.00) | SLC22A3MAPTADRB2TSHRKDM4E | |
| Metiprenaline SCHEMBL3226665 | 0.98 | SLC22A3 (1.00) | SLC22A3MAPTADRB2TSHRKDM4E | |
| Metiprenaline SCHEMBL2109418 | 0.98 | SLC22A3 (1.00) | SLC22A3MAPTADRB2TSHRKDM4E | |
| Metiprenaline SCHEMBL5319662 | 0.96 | SLC22A3 (0.94) | SLC22A3MAPTADRB2TSHRKDM4E | |
| SCHEMBL20852599 | 0.86 | SLC22A3 (0.78) | SLC22A3MAPTADRB2TSHRKDM4E | |
| SCHEMBL4882170 | 0.86 | SLC22A3 (0.77) | SLC22A3MAPTADRB2TSHRKDM4E | |
| Metanephrine SCHEMBL2471378 | 0.85 | SLC22A3 (0.71) | SLC22A3MAPTADRB2TSHRKDM4E | |
| Metanephrine SCHEMBL29569242 | 0.83 | SLC22A3 (0.73) | SLC22A3MAPTADRB2TSHRKDM4E | |
| Metanephrine SCHEMBL30512034 | 0.83 | SLC22A3 (0.73) | SLC22A3MAPTADRB2TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2117524-B1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NAT RES COUNCIL CANADA (CA) | 2019-08-14 | — | — | EP | disclosed |
| US-20170027888-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2017-02-02 | — | — | US | disclosed |
| US-20170027889-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2017-02-02 | — | — | US | disclosed |
| US-9351947-B2 | Use of catecholamines and related compounds as anti-angiogenic agents | NATIONAL RESEARCH COUNCIL OF CANADA | 2016-05-31 | — | — | US | disclosed |
| US-20100069401-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2010-03-18 | — | — | US | disclosed |
| EP-2117524-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | National Research Council of Canada (CA) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008092257-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170027888-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | ADRB3, ADRB1, ADRA1D | ADRB2 4/4885ADRB1 2/4885GAA 4603/4885 |
| US-20170027889-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | SLC6A2, VEGFA, COMT | ADRB2 7/4885ADRB1 4/4885GAA 842/4885 |
| US-20100069401-A1 | USE OF CATECHOLAMINES AND RELATED COMPOUNDS AS ANTI-ANGIOGENIC AGENTS | ADRB2, ADRB1, SLC6A2 | ADRB2 1/4885ADRB1 2/4885GAA 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.